The initiative aims to drive scientific advancements in the health and nutrition industry through microbiome modulation.
The scientific advisory board
The collaboration consists of Clasado’s R&D Director Dr. Lucien Harthoorn, CEO Per Rehné, and VP of B2B sales, Dr. Frederic Narbel.
Joining them are several external scientific advisors:
Prof Georg Holländer, head of the Department of Paediatrics at the University of Oxford and director of the Botnar Research Centre for Child Health in Basel, is an expert in immunology with a keen interest in thymus and T cell biology. He has reportedly authored over 100 publications in peer-reviewed journals.
Prof Matthias Kloor is deputy medical director at the Department of Applied Tumor Biology of the Institute of Pathology at Heidelberg University Hospital, and author of more than 190 publications in peer-reviewed scientific journals.
Prof Huub Savelkoul served as a professor in cell biology and immunology from 2000 to 2022 at Wageningen University, and has published almost 400 peer-reviewed research papers.
Clasado announced that working with these experts will “sharpen the scientific agenda” and allow the sharing of “valuable insights and experiences to propel the future of prebiotic development”.
Per Rehné adds: “As we look to the future of medical nutrition, gut microbiome modulation holds great potential and could play a key role in improving human health.
“Driven by rising global awareness, eyes are on the capabilities of prebiotics, which makes initiatives such as the new scientific advisory board all the more important.
“For us, this represents an opportunity to better understand where prebiotics can fit into healthcare strategies.”
Clasado works in the field of GOS technology, aiming to deliver clinically proven prebiotic solutions to improve human health.
It offers the prebiotic ingredient Bimuno and collaborates with manufacturers to create products that cater to the health and nutrition needs of consumers, including immunity, digestive health, and cognition.
With the appointment of the new advisory board, Clasado aims to continue the exploration of new applications of prebiotics in critical health areas.
This development comes after the firm received European Food Safety Authority (EFSA) approval extending the novel food status for GOS as a novel food in food for special medical purposes (FSMP) in the Spring of 2022.
Dr Lucien Harthoorn, R&D director at Clasado Biosciences, states: "The future of prebiotics, specifically galactooligosaccharides and potential novel oligosaccharides holds immense promise in the medical nutrition field – and we are working on uncovering the potential.”
Clasado boasts over 100 published scientific studies and more than 20 clinical trials that support Bimuno GOS.
Recently, a study revealed that daily consumption of 2.8g Bimuno GOS, reduced the duration of cold or flu-like symptoms in rugby players by an average of 2.4 days (24%) compared to the 10 days experienced by the placebo group.
One clinical trial found that 2.8 g/d Bimuno prebiotic administration could be an alternative to dietary restrictions for patients with functional gut symptoms.
Additionally, the US Military recently launched a clinical trial exploring the gut-brain access for stress, with the combination of B. longum R0175; L. helveticus R0052 (Cerebiome; Lallemand Health Solutions) with Clasado’s Bimuno-GOS.